Health News

Pathway Therapeutics, a drug discovery and development company founded in New Zealand, announced that it has met an important drug development milestone triggering a US$4.5 million fourth tranche of its Series A private equity placement. The financing was led by GBS Venture Partners, Australia and CM Capital Investments, Australia with co-investors the Breast Cancer Research Trust, the Trans-Tasman Commercialisation Fund, and the New Zealand Venture Investment Firm.

Read more

Filed under: Pharmacy News
Tags: Breast Cancer, cancer, Drug, Pharmacy

Related posts

• Zoledronic acid may extend survival in older breast cancer patients (0)
  A drug used to protect bone may extend survival in older breast cancer patients, according to researchers at the Universities of Sheffield and Leeds. Read more [tags] Pharmacy News [/tags]
  
  
• Women at high risk of developing breast cancer reluctant to take tamoxifen for prevention (0)
  Even when women at high-risk of breast cancer are well-informed about the risks and benefits of using the drug tamoxifen for prevention, only 6 percent said they were likely to take it. Read more [tags] Pharmacy News [/tags]
  
  
• USPTO issues patent covering method of metastatic breast cancer treatment using Bionovo’s Bezielle (0)
  Bionovo, Inc. announced today that the US Patent and Trademark Office (USPTO) has issued a patent covering a method of using Bionovo's proprietary drug candidate Bezielle® (BZL101) for the treatment of metastatic breast cancer. The patent issued today is Bionovo's second issued patent, with over 70 other patent applications currently pending. Read more [tags] Pharmacy News [/tags]
  
  
• US Oncology Research Network Participates In Phase III Follow-up Study To BiPar’s Investigational Cancer Drug BSI-201 (0)
  US Oncology, Inc. today announced that US Oncology Research will participate in the BiPar Sciences' Phase III, Multi-center, Open-Label, Randomized Trial of Gemcitabine/Carboplatin (G/C), with or without BSI-201, in patients with Estrogen Receptor (ER), Progesterone Receptor (PR), and HER2-negative metastatic breast cancer. Joyce O'Shaughnessy, M.D. Read more [tags] Pharmacy News [/tags]
  
  
• Unavailability of Avastin more dangerous risk for breast cancer patients, says FAMEDS founder (0)
  Breast cancer patients and their families will rally together on Tuesday, June 28, at 7:00 am outside of the Federal Drug Administration (FDA). At issue will be the FDA's final hearing to remove the anti-cancer drug Avastin from the approved medication list for treatment of late stage breast cancer, despite the FDA approving it [...]